| 1.69 0.07 (4.32%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.43  |
1-year : | 2.91 |
| Resists | First : | 2.08 |
Second : | 2.49 |
| Pivot price | 1.73 |
|||
| Supports | First : | 1.42 | Second : | 1.18 |
| MAs | MA(5) : | 1.57  |
MA(20) : | 1.83 |
| MA(100) : | 5.2 |
MA(250) : | 123.48 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 19.5 |
D(3) : | 11.3 |
| RSI | RSI(14): 36.4 |
|||
| 52-week | High : | 524 | Low : | 1.42 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CMND ] has closed above bottom band by 44.0%. Bollinger Bands are 84.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 42 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.71 - 1.71 | 1.71 - 1.72 |
| Low: | 1.58 - 1.59 | 1.59 - 1.6 |
| Close: | 1.68 - 1.69 | 1.69 - 1.7 |
Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lack adequate solutions. The company's research targets conditions such as alcohol use disorder (including problematic binge drinking), various eating disorders (like binge eating), depression, and other compulsive or "binge" behaviors. Founded in 2017, the company initially operated under the name Cyntar Ventures Inc. before officially rebranding as Clearmind Medicine Inc. in March 2021. Its operations are headquartered in Vancouver, Canada.
Thu, 30 Jul 2026
Clearmind's CMND-100 trial reaches 160 mg with no serious adverse events - Stock Titan
Tue, 28 Jul 2026
Clearmind Medicine Completes Treatment of All Participants in Part A of Phase I/II AUD Trial for CMND-100 - Quiver Quantitative
Tue, 28 Jul 2026
24 Participants Complete Treatment in Clearmind's Alcohol Use Disorder Trial - Stock Titan
Mon, 13 Jul 2026
Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial - marketscreener.com
Mon, 22 Jun 2026
Clearmind finishes 24-patient AUD trial stage; next phase awaits data review - Stock Titan
Thu, 18 Jun 2026
Clearmind Medicine Inc Share Price - CMND, RNS News, Articles, Quotes, & Charts (NASDAQ:CMND) - Proactive financial news
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 128.6 (%) |
| Shares Short | 88 (K) |
| Shares Short P.Month | 348 (K) |
| EPS | -175.92 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.27 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -51.4 % |
| Return on Equity (ttm) | -114.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -5.43 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0.14 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.41 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|